Compound Profile
PT 141 (Bremelanotide)
Melanocortin receptor agonist peptide
PT 141 is the research chemical name for bremelanotide, a melanocortin receptor agonist with an actual FDA approved product (Vyleesi) for hypoactive sexual desire disorder in premenopausal women; most gray market marketing (including to men, for erectile dysfunction) extends well beyond that narrow approved indication on much thinner evidence.
Use extra caution — Bremelanotide can transiently raise blood pressure and, in a subset of patients, cause a notable spike — Vyleesi carries specific dosing frequency limits partly for this reason, a meaningful consideration for anyone with cardiovascular risk factors. Details
At a glance
From this profile's structured data- Evidence
- Editorial grade not demonstrated by recorded studies
- Safety
- Bremelanotide can transiently raise blood pressure and, in a subset of patients, cause a notable spike — Vyleesi carries specific dosing-frequency limits partly for this reason, a meaningful consideration for anyone with cardiovascular risk factors.
- Profile context
- Melanocortin Receptor (MC3R/MC4R) Agonism, Central Nervous System Arousal Pathway Activation
Next stepsWhere to go next — guides & comparisons
Continue reading
- If you want to browse more compounds → All compounds
FDA-approved bremelanotide exists; gray-market PT-141 is not the same product
Bremelanotide is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women. A vial or powder sold online as PT-141, including one labeled for research use, has not thereby inherited Vyleesi’s FDA review or approved indication.
- Vyleesi is not indicated for men or to enhance sexual performance.
- Current labeling contraindicates Vyleesi in uncontrolled hypertension or known cardiovascular disease.
- Gray-market product quality, identity, concentration accuracy, and sterility should not be inferred from the approved drug’s evidence.
Regulatory status
2026 federal and state regulatory context
Vyleesi (bremelanotide) is FDA approved prescription only for HSDD in premenopausal women. RUO labeled PT 141 product is not legally intended for human consumption and is not the same regulatory entity as Vyleesi.
Quick stats
- Evidence level
- Needs review
- Typical onset
- Varies by prep
- Safety rating
- Use extra caution: Use caution
- Best for
- Melanocortin Receptor (MC3R/MC4R) Agonism, Central Nervous System Arousal Pathway Activation
- Avoid / review if
- Uncontrolled Hypertension, Pregnancy/Breastfeeding, Use In Postmenopausal Women Is Not Well Studied
Safety
Safety & Cautions
Bremelanotide can transiently raise blood pressure and, in a subset of patients, cause a notable spike — Vyleesi carries specific dosing frequency limits partly for this reason, a meaningful consideration for anyone with cardiovascular risk factors. Nausea is one of the most commonly reported trial side effects.
High caution
Caution level: High. Multiple caution categories apply, or the record uses avoid/contraindication language.
- Pregnancy/Breastfeeding CautionPregnancy or breastfeeding caution language is present.
Evidence-based safety
Caution when combined
Severity and certainty are shown separately. A high-priority caution can still be theoretical: these pairings are screened from shared contraindication mechanisms and are not automatically documented clinical interactions. Provenance identifies the source fields that produced each flag; it does not upgrade the certainty of the pairwise claim.
Moderate Caution
81 flagged pairingsBlood-pressure effects
Moderate Caution
81 flagged pairingsBlood-pressure effects
Representative pairings are shown below. Large mechanism groups are intentionally summarized to keep profiles focused and crawl-efficient.
Data provenance recorded for 81 of 81 pairings in this mechanism group.
- Agmatine sulfate — Theoretical interaction certainty
- ajoene — Theoretical interaction certainty
- Allicin — Theoretical interaction certainty
- American Ginseng Extract — Theoretical interaction certainty
- Andrographis — Theoretical interaction certainty
- Angelica Dahurica — Theoretical interaction certainty
- Astaxanthin — Theoretical interaction certainty
- Astragalus Membranaceus — Theoretical interaction certainty
- Beetroot extract — Theoretical interaction certainty
- Berberis — Theoretical interaction certainty
- Bicarbonate — Theoretical interaction certainty
- Black Seed — Theoretical interaction certainty
+69 more pairings share this mechanism. Use the Safety Checker to review a specific combination.
Evidence Summary
Profile-wide ·UnassignedEvidence lens
Treat this profile as unresolved until source review is complete.
Human clinical evidence: Not the primary signal
Mechanistic / preclinical: Mechanism mapped — Melanocortin Receptor (MC3R/MC4R) Agonism · Central Nervous System Arousal Pathway Activation
Research maturity: Theoretical / mechanistic research — Mechanistic or unresolved evidence is kept separate from established human outcomes.
Safety boundary: Safety note available — Bremelanotide can transiently raise blood pressure and, in a subset of patients, cause a notable spike — Vyleesi carries specific dosing frequency limits partly for this reason, a meaningful consideration for anyone with
Confidence estimate based on the design quality and consistency of published clinical trials.
PT 141 (Bremelanotide) has an evidence rating that is still under review.
How evidence grades work
Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.
- Strong
- Multiple RCTs, consistent direction, adequate effect size
- Moderate
- Some RCTs or consistent observational data in humans
- Preliminary / Mixed
- Animal or in-vitro only, or conflicting human data
- Traditional / Theoretical
- Traditional use only; no controlled human trials
How PT 141 (Bremelanotide) Works
Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.
Mechanism Pathway — How PT 141 (Bremelanotide) Works
Dosing
- No standardized dose
- No established consumer dosing protocol; see full guide article for regulatory and safety context.
Mechanisms & biological pathways
Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.
- Melanocortin Receptor (MC3R/MC4R) Agonism
- Central Nervous System Arousal Pathway Activation
- Central Melanocortin Signaling
Compare & Sourcing
Compare side-by-side tradeoffs or verify active marker guidelines.
Free safety checklist
Get the PT 141 (Bremelanotide) evidence notes
Occasional research updates, safety context, and product-quality checks for supplement decisions.
We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.
Sourcing options disabled for safety
Direct product recommendations and affiliate links are suppressed for this compound due to its high caution or needs-review safety classification.
Evaluate the safety checks, contraindications, and potential medication interactions above under clinician supervision before use.
Safety first · Harm reduction
This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.
Learn how we evaluate confidence, safety, and intensity on the methodology page.
Editorial Review
Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.
Help improve this profile
Was this useful for your research?
These controls record only the page and the structured choice you make when analytics consent is enabled. Please don’t include personal medical information in research requests.
Was this evidence summary clear?
Did you find what you were researching?
Compound profile context
How to interpret PT 141 (Bremelanotide)
PT 141 compound profile with evidence context, key research topics, source notes, safety context, and references presented in an evidence-first format. Use this compound profile to understand mechanism, evidence quality, and practical safety context before comparing products or building a stack. A biochemical pathway connection can be useful for discovery, but it is not the same as proven benefit in humans.
When reviewing PT 141 (Bremelanotide), separate the active molecule from the product category around it. Dose form, absorption, extract standardization, medication interactions, and individual sensitivity can change the real-world risk-benefit picture.
For supplement planning, avoid combining multiple compounds with overlapping sedating, stimulating, serotonergic, blood-pressure, anticoagulant, or liver-metabolism effects unless a qualified clinician has reviewed the context.